Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy

Prior treatment

• Presence of known factors causing systolic ventricular dysfunction:
  • Prior cardiomyopathy diagnosis.
  • Severe mitral or aortic valve disease.
  • Non-revascularizable ischemic heart disease.
  • Context of peri-resuscitation cardiopulmonary care.
  • Abusive alcohol consumption, defined as \>80 grams of ethanol or \>7 standard alcoholic beverages per day.
  • Active treatment with chemotherapeutic agents or radiation therapy to the thorax.
  • Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.

Age

• Age \<18 years.

Other

• Refusal of informed consent.
• Legal or juridical incapacity.
• Life expectancy less than 1 year.
• Impossibility of a follow-up of at least 6 months.
• Presence of a ventricular rate \>140 beats per minute, limiting the validity of imaging measurements.

• Presence of atrial fibrillation or atrial flutter not self-limited.
• Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \<50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \<50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.
• Signature of informed consent.
• Ability to understand and accept participation in the study.